Metabolites

Journal Browser

► Journal Browser

Special Issue Editors

Special Issue Information

Dear Colleagues,

This Special Issue is a continuation of our previous Special Issue, “Lipid Metabolism in Obesity and Diabetes 2023”.

Obesity is characterized by an excessive accumulation of fat, which leads to a plethora of medical complications including coronary artery disease, hypertension, type 2 diabetes mellitus, insulin resistance and dyslipidemia. Furthermore, enhanced atherogenesis and premature atherosclerosis are associated with the above-mentioned diseases and cause early cardiovascular complications and increased mortality. Previously, both harmful and beneficial effects of organokines, such as adipokines, hepatokines and gut hormones, have been observed for obesity and diabetes, especially in the regulation of glucose and lipid metabolism, insulin sensitivity, inflammation, vascular senescence and endogenous oxidative stress.

Due to the success of the first volume of this Special Issue, we welcome up-to-date reviews as well as clinical and original research articles studying lipid metabolism and/or organokine disturbances in the field of obesity; moreover, we welcome papers addressing related complications such as type 2 diabetes, dyslipidemias and atherosclerosis. The non-lipid effects of lipid-lowering and antidiabetic drugs in diabetes will also be covered.

Dr. Hajnalka Lőrincz
Dr. Mariann Harangi
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Metabolites is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Related Special Issue

Published Papers (1 paper)

Review

20 pages, 1068 KiB

Open AccessReview

Ketoacidosis and SGLT2 Inhibitors: A Narrative Review

by Carmela Morace, Giuseppe Lorello, Federica Bellone, Cristina Quartarone, Domenica Ruggeri, Annalisa Giandalia, Giuseppe Mandraffino, Letteria Minutoli, Giovanni Squadrito, Giuseppina T. Russo and Herbert Ryan Marini

Metabolites 2024, 14(5), 264; https://doi.org/10.3390/metabo14050264 - 6 May 2024

Viewed by 337

Abstract

An acute metabolic complication of diabetes mellitus, especially type 1, is diabetic ketoacidosis (DKA), which is due to an increase in blood ketone concentrations. Sodium/glucose co-transporter-2 inhibitor (SGLT2-i) drugs have been associated with the occurrence of a particular type of DKA defined as euglycemic (euDKA), characterized by glycemic levels below 300 mg/dL. A fair number of euDKA cases in SGLT2-i-treated patients have been described, especially in the last few years when there has been a significant increased use of these drugs. This form of euDKA is particularly insidious because of its latent onset, associated with unspecific symptomatology, until it evolves (progressing) to severe systemic forms. In addition, its atypical presentation can delay diagnosis and treatment. However, the risk of euDKA associated with SGLT2-i drugs remains relatively low, but it is essential to promptly diagnose and manage it to prevent its serious life-threatening complications. In this narrative review, we intended to gather current research evidence on SGLT2i-associated euDKA from randomized controlled trials and real-world evidence studies, its diagnostic criteria and precipitating factors. Full article

(This article belongs to the Special Issue Lipid Metabolism in Obesity and Diabetes, 2nd Edition)

► Show Figures